^
    Apply
    Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (NCT01282463)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/09/2019
    Initiation :
    04/01/2011
    Primary completion :
    02/01/2015
    Completion :
    03/01/2015
    KDR • FLT1 • VEGFB
    |
    docetaxel • Cyramza (ramucirumab) • icrucumab (IMC-18F1)
    Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (NCT01234402)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/14/2019
    Initiation :
    03/01/2011
    Primary completion :
    10/01/2013
    Completion :
    07/01/2017
    HER-2
    |
    HR positive • EGFR positive
    |
    capecitabine • Cyramza (ramucirumab) • icrucumab (IMC-18F1)